Clostridium botulinum produces the highly potent neurotoxin, botulinum neurotoxin (BoNT), which is classified into seven serotypes (A-G); the subtype classification is confirmed by the diversity of amino acid sequences among the serotypes. BoNT from the Osaka05 strain is associated with type B infant botulism and has been classified as BoNT/B subtype B6 (BoNT/B6) by phylogenetic analysis and the antigenicity of its C-terminal heavy chain (H C ) domain. However, the molecular bases for its properties, including its potency, are poorly understood. In this study, BoNT/B6 holotoxin was purified and the biological activity and receptor binding activity of BoNT/B6 compared with those of the previously-characterized BoNT/B1 and BoNT/B2 subtypes. The derivative BoNT/B6 was found to be already nicked and in an activated form, indicating that endogenous protease production may be higher in this strain than in the other two strains. BoNT/B1 exhibited the greatest lethal activity in mice, followed by BoNT/B6, which is consistent with the sensitivity of PC12 cells. No significant differences were seen in the enzymatic activities of the BoNT/Bs against their substrate. H C /B1 and H C /B6 exhibited similar binding affinities to synaptotagmin II (SytII), which is a specific protein receptor for BoNT/B. Binding to the SytII/ganglioside complex is functionally related to the toxic action; however, the receptor recognition sites are conserved. These results suggest that the distinct characteristics and differences in biological sensitivity of BoNT/B6 may be attributable to the function of its H c .domain.
botulism has recently been reported; however, foodborne botulism is rare. Most cases of infant botulism have been caused by proteolytic type A and B strains (2) .
BoNTs are released from C. botulinum as single polypeptides (150 kDa) that are nicked by an endogenous or exogenous protease such as trypsin or other trypsin-like enzymes. The nicked form of the neurotoxin is made up of a heavy chain (100 kDa) and a light chain (50 kDa) that are covalently linked by a disulfide bond. The heavy chain is further divided into two domains: the H N and H C domains (3) . The H C domain is responsible for binding to its receptor on the presynaptic membrane, this being the first step of its potent neurotoxicity. The H N domain is involved in pH-dependent translocation of the light chain into the cytosol, where the light chain acts by inhibiting neurotransmitter release (4) . The light chain functions as a zinc-dependent endopeptidase and cleaves N-ethylmaleimide-sensitive factor attachment protein receptor family proteins, which are important for neurotransmitter release. The different BoNT types are selective for specific proteins. Thus, BoNT/A and BoNT/E cleave synaptosomal-associated protein of 25 kDa, BoNT/B cleaves VAMP2, BoNT/C cleaves synaptosomal-associated protein of 25 kDa and syntaxin, and BoNT/D, BoNT/F and BoNT/G cleave VAMP1 and VAMP2 (5) . Recent studies have suggested that gangliosides are a shared protein receptor component of all seven BoNTs (6, 7) . However gangliosides are ubiquitous in the outer leaf of the plasma membrane and have a relatively low affinity for BoNTs (8) . The protein receptor is primarily considered to be the specific receptor for each BoNT. The protein receptors for BoNT/B are the homologous synaptic vesicle membrane proteins, SytI and SytII. Within specific protein receptors of BoNT/B, SytI reportedly has low affinity for the toxin, whereas SytII exhibits high affinity for ganglioside (9) , directly interacting with the toxin and mediating its internalization into neurons (10) .
Most BoNT serotypes have several subtypes, each of which have been confirmed by nucleotide sequencing analysis. BoNT/A has been subclassified into ten subtypes (A1 to A10) and BoNT/B into eight subtypes (B1 to B8) (11) . A few biological differences among the BoNT/A subtypes have been identified in rats and various neuronal cells (12) (13) (14) (15) .
We recently reported that the biological and functional differences between the BoNT/B B1 and B2 subtypes are caused by amino acid substitutions within the H C domain (8) . The ganglioside binding pocket of the H C domain and the catalytic light chain domain are highly conserved between subtypes; however, there are differences between the two residues (K1187 and E1190), which are located near or in the loop of the H C domain and considered important for ganglioside recognition. Differences in the electrical charge on the H C domain seem to affect its binding activity. Furthermore. we have recently determined the genetic and immunological characteristic of the type B strain Osaka05, which was classified as B6 subtype because Osaka05 has a unique BoNT/B gene sequence (as determined by phylogenetic analysis) and the antigenicity of its H C domain differs from those of BoNT/B1 and B2 (16) . However, only two type B strains isolated in Japan have been classified as B6 subtype in recent years (2) . The molecular bases underlying the interactions between each BoNT/B subtype and their cognate receptors have not been elucidated for other subtypes of BoNT/B, except for B1 and B2 subtypes.
Comparison of amino acid sequences has revealed only 98.5% similarity between BoNT/B subtypes B2 and B6, 95.7% similarity between B1 and B2 and 96.2% similarity between B1 and B6. Most of the amino acid substitutions in BoNT/B that result in differences between the three subtypes are located in the heavy chain sequence. It has also been observed that BoNT/B2 is less toxic than BoNT/B1, this difference being caused by the differential binding capabilities of the carboxyl terminal half of the H C domains (17) .
In this study, we investigated the biological activities of BoNT/B6 and compared the functional properties of this toxin with those of two other subtypes, BoNT/B1 and BoNT/B2.
MATERIALS AND METHODS
All the work described in this article was approved by the Bio-risk Committee of Osaka Prefecture University. All animal experiments were approved by and conducted according to Guidelines for Animal Experimentation of Osaka Prefecture University, Japan.
Purification of BoNT/B subtypes and toxicity determinations
Three C. botulinum type B strains, Okra, 111 and Osaka05, which produce BoNT/B1, BoNT/B2 and BoNT/B6 respectively, were used to purify each subtype, as previously described (18, 19) . Strains 111 and Osaka05 were each isolated from infants with type B botulism (16, 20) , whereas the Okra strain, which is associated with food-borne botulism, was used as an authentic BoNT/B. Trypsin treatment was carried out in 50 mM acetate buffer, pH 6.0 at 37°C for 15 min with trypsin (Sigma, St Louis, MO, USA) at a toxin-to-enzyme ratio (wt/wt) of 50:1. After treatment, a trypsin inhibitor from soybean (Wako, Osaka, Japan) was added to the reaction mixture at a toxin-to-enzyme ratio (wt/wt) of 100:1 and incubated at room temperature for 10 min. The BoNT/B subtypes were stored at À80°C until use. Purity was assessed by size separation of 1 mg of non-reduced and reduced toxins using 50 mM DTT (21) on a 10% polyacrylamide gel and the proteins were visualized by Coomassie brilliant blue staining. The activities of the three BoNT/B subtypes, as determined using the mouse bioassay described previously (22) , were periodically confirmed throughout the study.
The toxicity of purified BoNT/B6 was titrated by serial two-fold dilutions before i.p. injection into mice to determine the mean lethal dose (LD 50 ). Briefly, groups of four male ddY mice purchased from Japan SLC (Hamamatsu, Japan) (20 g body weight, 4 weeks old), were injected i.p. with 0.5 mL of gelatin phosphate buffer (50 mM sodium phosphate buffer, pH 6.2; 0.2% gelatin) containing serial dilutions of BoNT/B6. The mice were observed for four days from the time of injection or until death. Surviving and dead mice were counted and the specific activity of each treatment calculated according to the method proposed by Reed and Muench (23) . The time-to-death curve for BoNT/B6 was also determined using a previously reported method (24) . The specific activities of the three BoNT/B subtypes were assayed in mice by i.v. injection and then compared with those of BoNT/B1 and BoNT/B2.
Cleavage assay of recombinant VAMP2 by BoNT/B subtypes
Recombinant GST-tagged rat VAMP2 was purified on a glutathione sepharose 4B column, as described previously (25) . Briefly, DNA encoding full-length rat VAMP2 was cloned into pDEST15 (Thermo Fisher Scientific, Waltman, WY, USA) and the N-terminal GST-tag added to VAMP2 was used to purify the protein from Escherichia coli BL21-CodonPlus (DE3)-RIL cells (Agilent Technologies, Santa Clara, CA, USA) using immobilization affinity chromatography with glutathione sepharose 4B (GE Healthcare, Piscataway, NJ, USA). Four-fold dilutions of each BoNT/B subtype were prepared in triplicate. Each toxin was reduced for 30 min at 37°C in 10 mM Tris-HCl buffer, pH 7.5, containing 5 mM DTT and 20 mM NaCl. GST-tagged rat VAMP2 (10 mM) was incubated with each BoNT/B subtype in the same buffer at 37°C for 90 min and then analyzed by Coomassie brilliant blue staining. The extent of hydrolysis was monitored by densitometry (Scion Image; Scion, Frederick, MD, USA) The EC 50 was determined using GraphPad Prism 5 software (GraphPad Software, San Diego, CA, USA).
Plasmid constructions and recombinant protein production
The recombinant H C domain from BoNT/B6 (H C /B6, residues K854-E1291) was expressed and purified. The DNA fragment encoding H C /B6 was then cloned into the pQE30 vector (Qiagen, Hilden, DE, USA) for expression of the His-tagged H C /B6 fusion protein. Recombinant H C /B6 was expressed in E. coli M15 cells (Qiagen) and purified using a Ni-NTA Superflow column (Qiagen), as described previously (17) . The recombinant N-terminal region of rat SytII (residues M1-C87) was cloned into pMAL-c2 (New England BioLabs, Ipswich, MA, USA) expressed in E. coli DH5a cells (Takara, Shiga, Japan) as a fusion protein with a maltose binding protein tag, and then purified on amylose resin (New England BioLabs), as described previously (26) . POPC liposomes (5 mM; Avanti Polar Lipids, Alabaster, AL, USA) were prepared and desiccated at 37°C for 2 hrs in a rotary evaporator. After hydration with recombinant SytII solution (0.5 mM), the liposomes were suspended vigorously using a vortex mixer. Lipid suspensions were subjected to five freeze-thaw cycles (À180°C to 20°C) and vortex mixing (5 s). The resulting lipid suspensions were extruded 21 times through a 50 nm-pore polycarbonate filter (GE Healthcare) using an Avanti Mini-Extruder kit. The extruded solution was stored at 4°C prior to use.
Surface plasmon resonance analysis of H C /B-SytII interactions
An L1 sensor chip was used for the experiments and all SPR measurements were performed on a Biacore X100 (GE Healthcare) with HEPES-buffered saline running buffer (0.01 M HEPES, 0.15 M NaCl, pH 7.4). L1 sensor chip surfaces were washed with HEPES-buffered saline buffer and then treated with 0.5 mM lipid suspensions (immobilization level > 9000 RU). The reference and lipid surfaces were equalized with 10 mM NaOH and then blocked with 0.1 mg/mL BSA. The three H C /B subtypes (B1, B2 and B6) were used as analytes (concentration range, 50-1600 nM) to quantitate the kinetics of binding under a continuous flow rate of 30 mL/min at 25°C. The 1:1 binding model in BIA evaluation software (GE Healthcare) was used to analyze the binding kinetics.
Treatment of PC12 cells expressing SytII with BoNT/B subtypes
A DNA fragment encoding the full-length rat sytII sequence (residues M1-K442) was PCR amplified using the following primers: forward, 5 0 CACCATGA GAAA CATCTTCAAGAG3 0 and reverse, 5 0 GGTCGCATAAC TGAGGTATTGATAG3 0 . For directional cloning, the CACC sequence was added to the 5 0 end of the forward primer. The SytII gene was then cloned into pENTR/D-TOPO entry vector (Thermo Fisher Scientific) by directional cloning and then transferred to the destination vector, pcDNA3.2/V5-DEST (Thermo Fisher Scientific) to create an expression clone via an LR recombination reaction. The reaction mixture was then transformed into E. coli JM109. Successful integration of the SytII gene into the plasmid was confirmed by DNA sequencing and the plasmid was purified using a GeneElute Endotoxin Free Plasmid Midiprep kit (Sigma).
Rat adrenal pheochromocytoma PC12 cells endogenously express SytI but not SytII. Though both SytI and SytII exhibit receptor activities for BoNT/B, SytI-deficient PC12 cells were used to investigate the function of SytII, (27) . In brief, PC12 cells were seeded into polyethylenimine-coated 12-well culture dishes (Asahi Glass, Chiba, Japan) at a density of 2 Â 10 5 cells/well in RPMI 1640 medium (Wako) and penicillinstreptomycin solution (Sigma) with 5% FBS and 5% horse serum at 37°C in 5% CO 2 . For SytII expression, sytII/pcDNA3.2/V5-DEST was transfected into SytIdeficient PC12 cells using Lipofectamine 2000 (Thermo Fisher Scientific), as instructed by the manufacturer.
PC12 cells expressing SytII were washed with PBS, placed in high K þ buffer (50 mM KCl, 80 mM NaCl, 1.2 mM KH 2 PO 4 , 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , 10 mM glucose, pH 7.4), and then treated with different concentrations of the three BoNT/B subtypes (B1, B2, B6) at 37°C for 15 min. After incubation, the cells were placed in fresh RPMI-1640 medium and incubated at 37°C for 18 hr in 5% CO 2 . The cells were harvested using a rubber policeman and lysed with PBS containing 0.5% Triton X-100, 0.05% SDS and a cocktail of protease inhibitors (Sigma). After incubation for 30 min at 4°C, these samples were centrifuged at 13,000 g for 10 min. The supernatants were subjected to SDS-PAGE (12.5% polyacrylamide gel) for immunoblot analysis. After electrophoresis, the proteins were transferred onto polyvinylidene difluoride membranes and the membranes blocked with 5% skimmed milk-TBST (25 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 0.05% Tween20) for 1 hr at room temperature. The membranes were then incubated with the following antibodies: polyclonal anti-StgII (N-terminal peptides 1 to 20), monoclonal anti-b-actin (Sigma) and polyclonal anti-VAMP2 (Nterminal peptides 1 to 20), all of which were diluted in TBST containing 0.5% skimmed milk. Following three washes with TBST, the membranes were incubated with HRP-conjugated goat anti-rabbit or mouse IgG secondary antibodies (Bio-Rad, Hercules, CA, USA) in TBST.
Following three washes with TBST and treatment with SuperSignal WEST Femto Maximum Sensibility Substrate (Thermo Fisher Scientific), the reactive bands were visualized using a LAS-3000 image analyzer (GE Healthcare). The bands were quantified using Multi Gauge (version 3.0) software (GE Healthcare). EC 50 values were calculated using Prism 5 software (GraphPad Software).
Protein concentrations
Protein concentrations were determined by the method of Lowry et al. (28) or Bradford (29) with BSA or bovine gamma globulin as the standard, respectively.
RESULTS

BoNT/B6 properties and trypsin sensitivity
Attempts were made to purify this neurotoxin from cultures of the Osaka05 strain and to compare its molecular construction with that of the Okra and 111 strains. Progenitor toxins were purified by procedures similar to those used for purifying BoNT/B1 and BoNT/ B2 toxins, which were converted to the nicked forms by trypsin treatment. BoNT/B6 was isolated from the M toxin by anion exchange chromatography. The yield of purified BoNT/B6 was 19.1 mg from a 25 L culture. BoNT/B6 migrated to the same position as BoNT/B1 and BoNT/B2 in the absence of DTT and was converted into the nicked form even without trypsin treatment under reducing conditions on SDS-PAGE (Fig. 1) . BoNT/B6 was destroyed by trypsin treatment (data not shown). These results indicate that endogenous protease production of the Osaka05 strain is higher than that of the other strains. Fig. 1 . SDS-PAGE profiles of BoNT/B subtypes. Purified BoNT/B1, BoNT/B2 and BoNT/B6 samples were either non-reduced or reduced with DTT. The 150 kDa band represents the disulfide-linked BoNT/B, whereas the 100 kDa and 50 kDa bands represent the non-disulfidelinked heavy and light chains respectively. BoNT/B1 and BoNT/B2 were previously trypsinized whereas BoNT/B6 was not. NR, nonreduced; R, reduced.
Toxicities of BoNT/B6 in mice and PC12 cells expressing SytII
As BoNT/B6 seemed to be fully activated by an endogenous enzyme in cultures, attempts were made to compare its toxicity with or without trypsin. Toxic activity after treatment with trypsin decreased to 32% of that without trypsin; therefore, unlike BoNT/B1 and BoNT/B2, BoNT/B6 was used without trypsin treatment. BoNT/B6 exhibited a toxicity in mice of 2.55 Â 10 7 i.p. LD 50 /mg protein, this being only one-fifth as toxic as BoNT/B1 and twice as toxic as BoNT/B2 (Table 1) .
To evaluate the toxic activities of each BoNT/B subtype in vitro, PC12 cells transfected with sytII were prepared. SytI-deficient PC12 cells were used to eliminate the influence of SytI. SytII expression in PC12 cells was confirmed by immunofluorescence using an anti-SytII-antibody (data not shown). PC12 cells expressing SytII were exposed to each BoNT/B subtype and intracellular substrate cleavage monitored by immunoblotting. Amounts of VAMP2 decreased in a dose-dependent manner after treatment with each of the three BoNT/B subtypes. EC 50 values for BoNT/B1, BoNT/B2 and BoNT/B6 were 34.0, 202.5 and 95.6 nM, respectively, the EC 50 value for BoNT/B1 being approximately 6.0 and 2.8 times higher than those of BoNT/B2 and BoNT/B6, respectively (Fig. 2) . The degree of sensitivity thus determined is consistent with the results from the mouse LD 50 .
Enzymatic activities of BoNT/B1, B2 and B6 on recombinant VAMP2
The BoNT/B light chain cleaves the peptide bond between 76Q and 77F of rat VAMP2 (5) . After reduction of the BoNT/Bs with 5 mM DTT, the proteolytic activity of various concentrations of the three BoNT/B subtypes on recombinant GST-tagged rat VAMP2 were examined. GST-VAMP2 was hydrolyzed to the same extent by the BoNT/Bs. The EC 50 values were almost equivalent for each BoNT/B subtype, as determined by quantitative analysis of GST-VAMP2. Therefore, the proteolytic activities of the BoNT/B subtypes, as measured by the amounts of GST-VAMP2, did not differ significantly for any of the BoNT/B concentrations (Fig. 3) .
Binding specificities of H C /B
The binding specificities of H C /B to SytII were investigated using SPR analysis because the affinity of H C /B6 to SytII remains unclear. Both equilibrium association (k a ) and dissociation (k d ) rate constants were determined using sensorgram analysis with Biacore X100 Evaluation Software (GE Healthcare). The kinetic parameters K a and K d were calculated for each H C /B-SytII interaction. It was found that H C /B binds directly to Syt II and the kinetics parameters of the
). The K D value of H C /B2 was 5.44 Â 10 À7 , this being the lowest affinity (Fig. 4) .
DISCUSSION
Previous gene sequence and phylogenetic analysis of the BoNT/B Osaka05 strain, which was isolated in Japan in 2005 from an infant with botulism, revealed a new B subtype called B6 (16) . In this study, we purified BoNT/ B6 from the C. botulinum Osaka05 strain, as described previously, without relying on recombinant protein expression technology. Interestingly, even without trypsin treatment, DTT reduction of the 150 kDa BoNT/B6 resulted in distinct 100 kDa and 50 kDa bands, indicating that the derivative toxin produced by the Osaka05 strain is already nicked and in an activated form, which in turn indicates that endogenous protease production in this strain may be greater than in the other two strains. Because the toxicity of BoNT/B1 and BoNT/ B2 produced by the proteolytic type B strain increases four-to 30-fold after trypsin treatment (19, 30) , trypsinization of BoNT is involved in increasing its toxicity. However, when we examined the toxicity of BoNT/B6 after trypsin treatment, we found that it had decreased. This result suggests that BoNT/B6 is activated by an endogenous enzyme in the cultures.
We also compared the toxic activity of BoNT/B6 with those of BoNT/B1 and BoNT/B2. Of the BoNT/B subtypes tested herein, BoNT/B1 exhibited the highest lethal activity in mice and BoNT/B6 the second highest activity, these findings being consistent with the amout of VAMP2 cleavage in StgII-expressing PC12 cells treated with the three BoNT/B subtypes. The EC 50 of BoNT/B1 (34 nM) was about six-and three-fold higher than that of BoNT/B2 and BoNT/B6, respectively, in SytII-expressing PC12 cells (Fig. 2 and Table 1 ). This amount of toxin is consistent with the entry of BoNT/B1 observed in hippocampal neurons from SytI knockout mice that express SytII (31) . These results suggest that BoNT/B6 is less efficient at entering cells than BoNT/B1. Thus, BoNT/B6 may possess some characteristics that distinguish it from BoNT/B1 and BoNT/B2.
Although there were no significant differences between the enzymatic activities of each BoNT/B against the substrate (Fig. 3) , the differences in their toxic activity may have been attributable to the low degree of sequence similarity in the heavy chains of the three subtypes. We have previously shown that BoNT/B does not bind SytII in lipid vesicles without the GT1b ganglioside (8, 9) . However, results of previous studies have indicated that SytII directly binds BoNT/B more tightly than SytI in the absence of ganglioside (10, 32) . Therefore, we used SPR analysis to investigate the binding of H C /B to SytII, which we incorporated into lipid vesicles without ganglioside. In this experiment, H C /B1 and H C /B6 exhibited similar binding affinities for SytII, whereas the affinity of SytII for H C /B2 was lower than that of H C /B1 or H C /B6 (Fig. 4) . The K D for SytIIBoNT/B1 (0.544 mM) is consistent with previous data (32) . However, this value is approximately 1000 times lower than that in the presence of ganglioside (0.23 nM) reported previously (33) . Previous studies have also reported that binding and entry of BoNT/B to hippocampal neurons lacking ganglioside is diminished (31) . Moreover, ganglioside knock-out mice are less susceptible to BoNT/A, B and G in vivo (34) . Collectively, these results indicate that gangliosides do not directly mediate BoNT/B binding, but rather cooperate with SytII to form high affinity BoNT/B binding.
This study indirectly shows that the differences between BoNT/B1 and BoNT/B6 seem to rely on the H N domain. Interestingly, previous studies have shown that neutralization of surface carboxylates, which are located in the H N domain, disrupt translocation of the BoNT/B light chain (35) . A triple mutant of BoNT/B, one mutation being at the conserved charged residue in H N /B1 (E778), showed increased toxicity from a lack of charge repelling. Thus, E778 may be a key residue for H N /B6 toxicity because it is conserved between BoNT/B2 and BoNT/B6 and its carboxylate is slightly acidic. These results suggest that differences in biological activities between the BoNT/B subtypes may be attributable not only to the binding domain in the H C domain but also to the translocation domain of the H N region. Further research is required to determine the differential entry properties of the H N region.
The data presented here may be useful in the development of pharmaceutical BoNT; BoNTs of different serotypes or subtypes should be considered for future development. It is important to investigate the effects of changing an animal model into a cell-based model. Our results provide information relating to the basic potency of BoNT preparations.
